According to the American Association for the Study of Liver Diseases (AASLD) guidelines, pre-treatment, on-treatment and post-treatment monitoring of HCV levels in blood are recommended in patients receiving interferon (IFN)-free direct-acting antiviral (DAA) regimens11. Here, IFNA1 is linked to liver disorder.